MX2016004329A - Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab. - Google Patents

Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.

Info

Publication number
MX2016004329A
MX2016004329A MX2016004329A MX2016004329A MX2016004329A MX 2016004329 A MX2016004329 A MX 2016004329A MX 2016004329 A MX2016004329 A MX 2016004329A MX 2016004329 A MX2016004329 A MX 2016004329A MX 2016004329 A MX2016004329 A MX 2016004329A
Authority
MX
Mexico
Prior art keywords
benralizumab
methods
chronic obstructive
obstructive pulmonary
treating chronic
Prior art date
Application number
MX2016004329A
Other languages
English (en)
Spanish (es)
Inventor
Wang Bing
Roskos Lorin
Ward Christine
Van Der Merwe Rene
Martin Ubaldo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2016004329A publication Critical patent/MX2016004329A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2016004329A 2013-10-15 2014-10-14 Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab. MX2016004329A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361891175P 2013-10-15 2013-10-15
US201461970126P 2014-03-25 2014-03-25
PCT/US2014/060432 WO2015057668A1 (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab

Publications (1)

Publication Number Publication Date
MX2016004329A true MX2016004329A (es) 2016-11-10

Family

ID=52809872

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016004329A MX2016004329A (es) 2013-10-15 2014-10-14 Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.
MX2019013468A MX2019013468A (es) 2013-10-15 2016-04-04 Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019013468A MX2019013468A (es) 2013-10-15 2016-04-04 Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.

Country Status (12)

Country Link
US (4) US20150104447A1 (https=)
EP (2) EP3485902A1 (https=)
JP (3) JP2016534996A (https=)
KR (1) KR20160061352A (https=)
CN (2) CN113230399A (https=)
AU (2) AU2014334563A1 (https=)
BR (1) BR112016008082A2 (https=)
CA (1) CA2925402A1 (https=)
MX (2) MX2016004329A (https=)
RU (1) RU2706729C2 (https=)
SG (2) SG10201807318RA (https=)
WO (1) WO2015057668A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2687043C2 (ru) 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR20210094669A (ko) 2013-04-29 2021-07-29 에프. 호프만-라 로슈 아게 인간 fcrn-결합 변형된 항체 및 사용 방법
RU2698969C2 (ru) 2014-01-15 2019-09-02 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с улучшенной способностью связываться с белком а
AU2016272399B2 (en) 2015-06-01 2021-09-09 Kyowa Kirin Co., Ltd. Therapeutic agent and therapeutic method for pulmonary hypertension
CN109544378B (zh) * 2018-10-27 2024-06-25 平安医疗健康管理股份有限公司 一种肺源性心脏病资质认证方法、设备及服务器
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
BR112022010934A2 (pt) * 2019-12-06 2022-11-29 Sanofi Biotechnology Métodos para tratar copd administrando um antagonista de il-33
EP3957308A1 (en) 2020-08-21 2022-02-23 Palobiofarma, S.L. (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
WO2023034993A1 (en) * 2021-09-03 2023-03-09 Gleich Gerald J Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241944C (zh) * 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
EP1176195B1 (en) * 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7404953B2 (en) * 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060014680A1 (en) * 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
HUE036885T2 (hu) * 2007-05-14 2018-08-28 Astrazeneca Ab Eljárás a bazofil-szint csökkentésére
CN101249093A (zh) * 2008-03-19 2008-08-27 李虎山 一种治疗慢性阻塞性肺部疾病的组合物
MX2013004212A (es) * 2010-10-15 2013-09-02 Medimmune Ltd Terapias para mejorar la funcion pulmonar.
TWI732259B (zh) * 2010-12-16 2021-07-01 美商建南德克公司 關於th2抑制作用之診斷及治療
EP2710370A4 (en) * 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
HK1201440A1 (en) * 2011-11-01 2015-09-04 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
CN111617244A (zh) * 2013-08-12 2020-09-04 阿斯特拉捷利康股份公司 使用贝那利珠单抗改善哮喘症状的方法
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
US9441046B2 (en) * 2013-08-12 2016-09-13 Astrazeneca Ab Methods for increasing forced expiratory volume in asthmatics using benralizumab

Also Published As

Publication number Publication date
AU2014334563A1 (en) 2016-04-07
SG11201601807XA (en) 2016-04-28
JP6870037B2 (ja) 2021-05-12
RU2016118425A3 (https=) 2018-07-19
KR20160061352A (ko) 2016-05-31
JP2016534996A (ja) 2016-11-10
MX2019013468A (es) 2020-02-12
JP2019203009A (ja) 2019-11-28
RU2706729C2 (ru) 2019-11-20
JP2021107421A (ja) 2021-07-29
CA2925402A1 (en) 2015-04-23
CN113230399A (zh) 2021-08-10
EP3057609A1 (en) 2016-08-24
US20180291108A1 (en) 2018-10-11
US20200123262A1 (en) 2020-04-23
RU2016118425A (ru) 2017-11-21
SG10201807318RA (en) 2018-09-27
EP3485902A1 (en) 2019-05-22
CN105636607A (zh) 2016-06-01
US20150104447A1 (en) 2015-04-16
EP3057609A4 (en) 2017-03-22
BR112016008082A2 (pt) 2017-10-17
AU2020202333A1 (en) 2020-04-23
US20170107291A1 (en) 2017-04-20
WO2015057668A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
MX2019013468A (es) Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.
PH12015502075B1 (en) Treatment of cataplexy
MX2023000079A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento de sinusitis cronica con polipos nasales.
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
PL3791896T3 (pl) Terapia skojarzona obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu
PH12015501108B1 (en) Treatment of pulmonary disease
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
MX2015017970A (es) Metodos para tratar la poliposis nasal mediante la administracion de un antagonista de il-4r.
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
NZ710726A (en) Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
EA201990684A1 (ru) Способы применения оксигенированных холестеролсульфатов (ocs)
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
MX2016001383A (es) Metodos para reducir la tasa de exacerbacion de asma mediante el uso de benralizumab.
EA201491286A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
NZ629828A (en) Methods for the treatment of b cell-mediated inflammatory diseases
EA201590883A1 (ru) Лечение помалидомидом рака у субъекта с почечной недостаточностью
MX2015013066A (es) Usos terapéuticos para anticuerpos contra vegfr1.
MX368474B (es) Uso de benralizumab para mejorar síntomas de asma.
MX2016001384A (es) Metodos para incrementar el volumen espiratorio forzado en pacientes asmaticos que usan benralizumab.
MX351189B (es) Inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares.
EA201792282A1 (ru) Способы лечения заболеваний
EA201491581A1 (ru) Везикулярные композиции
EA201690446A1 (ru) Лечение множественной миеломы
EA201690445A1 (ru) Лечение рака